SSB Expression is Associated with Metabolic Parameters of F-FDG PET/CT in Lung Adenocarcinoma and Can Improve Diagnostic Efficiency

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Dec 6

PMID 39641036

Authors

Zi-Yue Liu

Ling-Ling Yuan

Yan Gao

Yu Zhang

Yao-Hua Zhang

Yi Yang

Yu-Xuan Chen

Xu-Sheng Liu

Zhi-Jun Pei

Affiliations

Soon will be listed here.

Abstract

Purpose: The study evaluates the expression and functional significance of the Small RNA Binding Exonuclease Protection Factor La (SSB) gene in lung adenocarcinoma (LUAD). By utilizing F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) machines, we correlated SSB gene expression with PET/CT parameters, as well as its value in LUAD diagnosis.

Methods: Fifty-five patients with LUAD underwent F-FDG PET/CT imaging prior to pulmonary surgery. Metabolic parameters such as maximum standardized uptake values (SUV) were quantitatively calculated from the F-FDG PET/CT imaging data. The diagnostic value was compared with that of thyroid transcription factor 1 (TTF1, the current standard-of-care). Publicly procurable datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used to establish SSB gene expression patterns across diverse cancer types and specifically in LUAD, along with its associations with glycolysis and N6-methyladenosine (m6A) modification.

Results: SSB was highly expressed in LUAD compared to adjacent non-cancerous tissues. SSB additionally demonstrated superior diagnostic utility for LUAD compared to TTF1. The correlation between SSB and SUV as well as average standardized uptake values (SUV) was positive (P < 0.001), while TTF1 displayed a negative correlation with metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (P < 0.05).

Conclusion: In LUAD, SSB expression correlated with high metabolic activity (SUV) on F-FDG PET/CT imaging. SSB is not only an important prognostic marker for lung cancer metastases, but may also represent a novel therapeutic target.

References

Chetan M, Gleeson F . Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. Eur Radiol. 2020; 31(2):1049-1058. PMC: 7813733. DOI: 10.1007/s00330-020-07141-9. View

Chung H, Lee K, Kim H, Kim W, So Y . FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2013; 140(1):89-98. DOI: 10.1007/s00432-013-1545-7. View

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou Y . mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020; 19(1):53. PMC: 7066851. DOI: 10.1186/s12943-020-01170-0. View

Gyorffy B, Surowiak P, Budczies J, Lanczky A . Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8(12):e82241. PMC: 3867325. DOI: 10.1371/journal.pone.0082241. View

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino G . Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016; 43(11):1954-61. DOI: 10.1007/s00259-016-3425-2. View

Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik A, Patil D . Reversible methylation of mA in the 5' cap controls mRNA stability. Nature. 2016; 541(7637):371-375. PMC: 5513158. DOI: 10.1038/nature21022. View

Berghmans T, Paesmans M, Mascaux C, Martin B, Meert A, HALLER A . Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006; 17(11):1673-6. DOI: 10.1093/annonc/mdl287. View

Myong N . Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. J Korean Med Sci. 2003; 18(4):494-500. PMC: 3055086. DOI: 10.3346/jkms.2003.18.4.494. View

Liu X, Yuan L, Gao Y, Ming X, Zhang Y, Zhang Y . DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma. J Transl Med. 2023; 21(1):574. PMC: 10463715. DOI: 10.1186/s12967-023-04454-3. View

10.

Tarter L, Bermas B . Expert Perspective on a Clinical Challenge: Lupus and Pregnancy. Arthritis Rheumatol. 2023; 76(3):321-331. DOI: 10.1002/art.42756. View

11.

Luna H, Imasa M, Juat N, Hernandez K, Sayo T, Cristal-Luna G . Expression landscapes in non-small cell lung cancer shaped by the thyroid transcription factor 1. Lung Cancer. 2023; 176:121-131. DOI: 10.1016/j.lungcan.2022.12.015. View

12.

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X . Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer Res. 2023; 83(13):2187-2207. DOI: 10.1158/0008-5472.CAN-22-3059. View

13.

Wang L, Ruan M, Lei B, Yan H, Sun X, Chang C . The potential of F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer. Lung Cancer. 2020; 150:44-52. DOI: 10.1016/j.lungcan.2020.10.004. View

14.

Fang H, Sun Q, Zhou J, Zhang H, Song Q, Zhang H . mA methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma. Mol Cancer. 2023; 22(1):99. PMC: 10288689. DOI: 10.1186/s12943-023-01791-1. View

15.

Liu X, Yuan L, Gao Y, Zhou L, Yang J, Pei Z . Overexpression of METTL3 associated with the metabolic status on F-FDG PET/CT in patients with Esophageal Carcinoma. J Cancer. 2020; 11(16):4851-4860. PMC: 7330681. DOI: 10.7150/jca.44754. View

16.

Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S . Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. Cancer Cell. 2018; 33(3):368-385.e7. DOI: 10.1016/j.ccell.2018.01.010. View

17.

Liu X, Gao Y, Kui X, Liu X, Zhang Y, Zhang Y . High expression of HNRNPR in ESCA combined with F-FDG PET/CT metabolic parameters are novel biomarkers for preoperative diagnosis of ESCA. J Transl Med. 2022; 20(1):450. PMC: 9533615. DOI: 10.1186/s12967-022-03665-4. View

18.

Yang J, Yuan L, Gao Y, Liu X, Wang Y, Zhou L . F-FDG PET/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer. J Cancer. 2021; 12(19):5838-5847. PMC: 8408126. DOI: 10.7150/jca.57926. View

19.

Sommer G, Dittmann J, Kuehnert J, Reumann K, Schwartz P, Will H . The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene. 2010; 30(4):434-44. DOI: 10.1038/onc.2010.425. View

20.

Liu X, Zhou L, Yuan L, Gao Y, Kui X, Liu X . NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Front Immunol. 2021; 12:724741. PMC: 8324208. DOI: 10.3389/fimmu.2021.724741. View